| A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader HT Huang, D Dobrovolsky, J Paulk, G Yang, EL Weisberg, ZM Doctor, ... Cell chemical biology 25 (1), 88-99. e6, 2018 | 423 | 2018 |
| Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models MC Silva, FM Ferguson, Q Cai, KA Donovan, G Nandi, D Patnaik, T Zhang, ... elife 8, e45457, 2019 | 245 | 2019 |
| NUAK2 is a critical YAP target in liver cancer WC Yuan, B Pepe-Mooney, GG Galli, MT Dill, HT Huang, M Hao, Y Wang, ... Nature communications 9 (1), 4834, 2018 | 122 | 2018 |
| MELK is not necessary for the proliferation of basal-like breast cancer cells HT Huang, HS Seo, T Zhang, Y Wang, B Jiang, Q Li, DL Buckley, B Nabet, ... Elife 6, e26693, 2017 | 115 | 2017 |
| Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases S Banerjee, SJ Buhrlage, HT Huang, X Deng, W Zhou, J Wang, R Traynor, ... Biochemical Journal 457 (1), 215-225, 2014 | 83 | 2014 |
| Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival Y Wang, M Begley, Q Li, HT Huang, A Lako, MJ Eck, NS Gray, ... Proceedings of the National Academy of Sciences 113 (35), 9810-9815, 2016 | 75 | 2016 |
| An efficient synthesis of fluorinated azaheterocycles by aminocyclization of alkenes HT Huang, TC Lacy, B Błachut, GX Ortiz Jr, Q Wang Organic letters 15 (8), 1818-1821, 2013 | 72 | 2013 |
| Synergistic interactions with PI3K inhibition that induce apoptosis Y Zwang, O Jonas, C Chen, ML Rinne, JG Doench, F Piccioni, L Tan, ... elife 6, e24523, 2017 | 32 | 2017 |
| Stable isotope labeling strategy for protein–ligand binding analysis in multi-component protein mixtures PD DeArmond, GM West, HT Huang, MC Fitzgerald Journal of the American Society for Mass Spectrometry 22 (3), 418-430, 2011 | 22 | 2011 |
| Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates HT Huang, RJ Lumpkin, RW Tsai, S Su, X Zhao, Y Xiong, J Chen, ... Nature Chemical Biology, 1-10, 2024 | 13 | 2024 |
| Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. Elife 8 MC Silva, FM Ferguson, Q Cai, KA Donovan, G Nandi, D Patnaik, T Zhang, ... | 10 | 2019 |
| Tricyclic kinase inhibitors of MELK and methods of use N Gray, T Zhang, HT Huang, Y Wang, J Zhao, HG Choi US Patent 10,544,138, 2020 | 8 | 2020 |
| NUAK2 is a critical YAP target in liver cancer. Nat. Commun. 9, 4834 WC Yuan, B Pepe-Mooney, GG Galli, MT Dill, HT Huang, M Hao, Y Wang, ... | 6 | 2018 |
| Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use NS Gray, D Dobrovolsky, HT Huang US Patent 10,925,967, 2021 | 3 | 2021 |
| Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use NS Gray, D Dobrovolsky, HT Huang US Patent 10,842,878, 2020 | 2 | 2020 |
| Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use NS Gray, D Dobrovolsky, HT Huang US Patent 11,730,818, 2023 | 1 | 2023 |
| A ubiquitin-specific proximity labeling method to study drug-induced ubiquitylation HT Huang, RJ Lumpkin, RW Tsai, KA Donovan, S Su, X Zhao, J Chen, ... Cancer Research 84 (6_Supplement), 3885-3885, 2024 | | 2024 |
| Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use NS Gray, D Dobrovolsky, HT Huang US Patent App. 18/214,825, 2023 | | 2023 |
| Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use NS Gray, J Bradner, L Tan, HT Huang, D Buckley, G Winter, ... US Patent 10,925,868, 2021 | | 2021 |
| Salicylate inhibitors of MELK and methods of use N Gray, T Zhang, HT Huang, Y Wang, J Zhao, HG Choi US Patent 10,875,844, 2020 | | 2020 |
